Michael J. Wagner

5.0k total citations · 1 hit paper
97 papers, 2.9k citations indexed

About

Michael J. Wagner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Rheumatology. According to data from OpenAlex, Michael J. Wagner has authored 97 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 22 papers in Rheumatology. Recurrent topics in Michael J. Wagner's work include Sarcoma Diagnosis and Treatment (44 papers), Vascular Tumors and Angiosarcomas (16 papers) and Bone Tumor Diagnosis and Treatments (15 papers). Michael J. Wagner is often cited by papers focused on Sarcoma Diagnosis and Treatment (44 papers), Vascular Tumors and Angiosarcomas (16 papers) and Bone Tumor Diagnosis and Treatments (15 papers). Michael J. Wagner collaborates with scholars based in United States, United Kingdom and Germany. Michael J. Wagner's co-authors include Dan E. Wells, William C. Summers, Susan H. Blanton, Jung Ahn, Robert G. Maki, Bernhard Horsthemke, Jacqueline T. Hecht, Alexander J. Lazar, Wei‐Lien Wang and Brendan Lee and has published in prestigious journals such as Nucleic Acids Research, Circulation and Nature Genetics.

In The Last Decade

Michael J. Wagner

89 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model

2017 242 citations Michael J. Wagner, Robert G. Maki et al. profile →

Peers

Countries citing papers authored by Michael J. Wagner

Since Specialization

Citations

This map shows the geographic impact of Michael J. Wagner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Wagner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Wagner more than expected).

Fields of papers citing papers by Michael J. Wagner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Wagner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Wagner. The network helps show where Michael J. Wagner may publish in the future.

Co-authorship network of co-authors of Michael J. Wagner

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Wagner. A scholar is included among the top collaborators of Michael J. Wagner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Wagner. Michael J. Wagner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets 2025 ·JCO Precision Oncology ·Michael J. Wagner, Erica Pimenta, (unknown), Elizabeth T. Loggers, J. Scott Roberts, (unknown), Eleanor Y. Chen, Robert W. Ricciotti, Candace L. Haddox, R J Berg, (unknown), Melissa C. Stoppler, James L. Chen, Lee D. Cranmer	0
2	Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report 2024 ·ESMO Open ·Patrick Schöffski, Robin L. Jones, Mark Agulnik, Jean‐Yves Blay, A. Chalmers, (unknown), Daniel Pink, Silvia Stacchiotti, (unknown), Bruno Vincenzi, Michael J. Wagner, Robert G. Maki	1
3	1979P phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS) 2023 ·Annals of Oncology ·Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, (unknown), Gaurav Goyal, Manoj Menon, Thomas Odeny, Elad Sharon, Michael J. Wagner, Chi‐Chuan Wang, Nina Bhardwaj, Maher Abdul‐Hay, Judith C. Kaiser, Alan F. Wright, Robert Yarchoan, Steven P. Fling, Qiang Lü, Thomas S. Uldrick	2
4	Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406) 2023 ·Clinical Cancer Research ·Lee D. Cranmer, (unknown), (unknown), Karla V. Ballman, Elizabeth T. Loggers, Seth M. Pollack, Michael J. Wagner, Denise K. Reinke, Patrick Schöffski, William D. Tap	1
5	Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids? 2023 ·Cancers ·(unknown), Lara E. Davis, Catherine M. Albert, Brian L. Samuels, (unknown), Michael J. Wagner	18
6	Oncogenic role of a developmentally regulated NTRK2 splice variant 2022 ·Science Advances ·Siobhan S. Pattwell, Sonali Arora, (unknown), Michael Zager, Keith R. Loeb, Patrick J. Cimino, (unknown), (unknown), Hamid Bolouri, (unknown), Frank Szulzewsky, Vaishnavi V. Phadnis, Tatsuya Ozawa, Michael J. Wagner, Michael C. Haffner, Junyue Cao, Jay Shendure, Eric C. Holland	3
7	Sarcoma Care Collaborations: Models for patient centered sub-specialty oncology care in the COVID-19 era and beyond 2022 ·Michael J. Wagner, Majid Chalian, Robert W. Ricciotti, (unknown), Matthew J. Thompson, Stephanie K. Schaub	0
8	CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes 2021 ·Journal for ImmunoTherapy of Cancer ·Brett Schroeder, (unknown), Bonnie LaFleur, Rachel Gittelman, Marissa Vignali, (unknown), Kevin C. Flanagan, Julie Rytlewski, Laura Riolobos, Brian Schulte, Teresa S. Kim, Eleanor Y. Chen, Kimberly S. Smythe, Michael J. Wagner, José G. Mantilla, Jean S. Campbell, Robert H. Pierce, Robin L. Jones, Lee D. Cranmer, Seth M. Pollack	25
9	Two cases of aggressive sarcomatoid urothelial carcinoma reveal potential molecular targets 2021 ·(unknown), (unknown), Jihyun Ahn, Judith C. Hagedorn, Eric Q. Konnick, Robin L. Bennett, Petros Grivas, Michael J. Wagner, Nicholas P. Reder, Sarah P. Psutka	1
10	Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA) 2017 ·Molecular Cancer Therapeutics ·Michael J. Wagner, Rahul Mitra, Mark J. McArthur, Wallace B. Baze, (unknown), Sherry Y. Wu, Cristian Rodriguez‐Aguayo, Xinna Zhang, Robert L. Coleman, Gabriel Lopez‐Berestein, Anil K. Sood	101
11	Synovial Sarcoma of the Head and Neck: A Single Institution Review 2017 ·Sarcoma ·Vancheswaran Gopalakrishnan, Behrang Amini, Michael J. Wagner, (unknown), Alexander J. Lazar, Patrick P. Lin, Robert S. Benjamin, Dejka M. Araujo	25
12	Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients 2017 ·Scientific Reports ·Gustavo Schvartsman, Michael J. Wagner, Behrang Amini, Chrystia M. Zobniw, Van Anh Trinh, Andrea Barbo, Heather Lin, Wei‐Lien Wang, Anthony P. Conley, Vinod Ravi, Dejka M. Araujo, Maria A. Zarzour, Robert S. Benjamin, Shreyaskumar Patel, Neeta Somaiah	17
13	Endothelial cell malignancies: new insights from the laboratory and clinic 2017 ·npj Precision Oncology ·Michael J. Wagner, Vinod Ravi, David G. Menter, Anil K. Sood	28
14	Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer 2016 ·Molecular Cancer Therapeutics ·Yan Huang, Lenard M. Lichtenberger, Morgan Taylor, Justin Bottsford-Miller, Monika Haemmerle, Michael J. Wagner, Yasmin Lyons, Sunila Pradeep, Wei Hu, Rebecca A. Previs, Jean M. Hansen, Dexing Fang, Piotr L. Dorniak, Justyna Filant, Elizabeth J. Dial, Fangrong Shen, Hiroto Hatakeyama, Anil K. Sood	42
15	A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments 2015 ·BMC Cancer ·Michael J. Wagner, (unknown), (unknown), Caroline Korves, (unknown), Stephanie Manson, (unknown), Maureen P. Neary, George D. Demetri	22
16	A Randomized Comparison of Proximal and Distal Ultrasound‐Guided Adductor Canal Catheter Insertion Sites for Knee Arthroplasty 2014 ·Journal of Ultrasound in Medicine ·Edward R. Mariano, T. Edward Kim, Michael J. Wagner, (unknown), T. Kyle Harrison, (unknown), Nicholas J. Giori, Steven T. Woolson, (unknown), Steven K. Howard	43
17	Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer 2013 ·Frontiers in Oncology ·Michael J. Wagner, Robert G. Maki	10
18	Congenital muscular dystrophy with laminin α2 chain deficiency: Identification of a new intermediate phenotype and correlation of clinical findings to muscle immunohistochemistry 1996 ·European Journal of Pediatrics ·Ralf Herrmann, Volker Straub, Klaus L. Meyer, T Kahn, Michael J. Wagner, Thomas Voit	52
19	Integrated Mapping Analysis of the Werner Syndrome Region of Chromosome 8 1994 ·Genomics ·Junko Oshima, Chang-En Yu, Michael Boehnke, James L. Weber, Susanne Edelhoff, Michael J. Wagner, Dan E. Wells, Stephen Wood, Christine M. Distèche, George M. Martin, Gerard D. Schellenberg	21
20	Molecular analysis of overlapping chromosomal deletions in patients with Langer-Giedion syndrome 1991 ·Genomics ·Julia Parrish, Michael J. Wagner, Jacqueline T. Hecht, Charles I. Scott, Dan E. Wells	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact